These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2923387)

  • 1. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism.
    Greenspan SL; Oppenheim DS; Klibanski A
    Ann Intern Med; 1989 Apr; 110(7):526-31. PubMed ID: 2923387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoporosis in men with hyperprolactinemic hypogonadism.
    Greenspan SL; Neer RM; Ridgway EC; Klibanski A
    Ann Intern Med; 1986 Jun; 104(6):777-82. PubMed ID: 3706929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptomatic osteoporosis in a man with hyperprolactinemic hypogonadism.
    Jackson JA; Kleerekoper M; Parfitt AM
    Ann Intern Med; 1986 Oct; 105(4):543-5. PubMed ID: 3752759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated serum lipids in hypogonadal men with and without hyperprolactinemia.
    Oppenheim DS; Greenspan SL; Zervas NT; Schoenfeld DA; Klibanski A
    Ann Intern Med; 1989 Aug; 111(4):288-92. PubMed ID: 2757313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of prolactin and estrogen deficiency in amenorrheic bone loss.
    Klibanski A; Biller BM; Rosenthal DI; Schoenfeld DA; Saxe V
    J Clin Endocrinol Metab; 1988 Jul; 67(1):124-30. PubMed ID: 3379129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vertebral fractures in males with prolactinoma.
    Mazziotti G; Porcelli T; Mormando M; De Menis E; Bianchi A; Mejia C; Mancini T; De Marinis L; Giustina A
    Endocrine; 2011 Jun; 39(3):288-93. PubMed ID: 21479837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.
    Di Somma C; Colao A; Di Sarno A; Klain M; Landi ML; Facciolli G; Pivonello R; Panza N; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1998 Mar; 83(3):807-13. PubMed ID: 9506732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism.
    Finkelstein JS; Klibanski A; Neer RM; Greenspan SL; Rosenthal DI; Crowley WF
    Ann Intern Med; 1987 Mar; 106(3):354-61. PubMed ID: 3544993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bone tissue in patients with hyperprolactinemic hypogonadism].
    Rozhinskaia LIa; Marova EI; Dzeranova LK; Rassokhin BM; Purtova GS; Goncharov NP; Mishchenko BP; Ilovaĭskaia IA
    Probl Endokrinol (Mosk); 1992; 38(6):17-9. PubMed ID: 1302840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Has prolactin a role in the hypogonadal status of HIV-infected patients?
    Collazos J; Esteban M
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(1):43-6. PubMed ID: 19171915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increase in bone mass after treatment of hyperprolactinemic amenorrhea.
    Klibanski A; Greenspan SL
    N Engl J Med; 1986 Aug; 315(9):542-6. PubMed ID: 3736637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism.
    Katznelson L; Rosenthal DI; Rosol MS; Anderson EJ; Hayden DL; Schoenfeld DA; Klibanski A
    AJR Am J Roentgenol; 1998 Feb; 170(2):423-7. PubMed ID: 9456958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism.
    Finkelstein JS; Klibanski A; Neer RM; Doppelt SH; Rosenthal DI; Segre GV; Crowley WF
    J Clin Endocrinol Metab; 1989 Oct; 69(4):776-83. PubMed ID: 2674186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study.
    Amin S; Zhang Y; Sawin CT; Evans SR; Hannan MT; Kiel DP; Wilson PW; Felson DT
    Ann Intern Med; 2000 Dec; 133(12):951-63. PubMed ID: 11119396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.
    Katznelson L; Finkelstein JS; Schoenfeld DA; Rosenthal DI; Anderson EJ; Klibanski A
    J Clin Endocrinol Metab; 1996 Dec; 81(12):4358-65. PubMed ID: 8954042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperprolactinemia in oligospermic Nigerian males: effect of bromocriptine treatment.
    Modebe O
    Int J Fertil Menopausal Stud; 1994; 39(2):95-9. PubMed ID: 8012447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Follow-Up of Primary Medical Versus Surgical Treatment of Prolactinomas in Men: Effects on Hyperprolactinemia, Hypogonadism, and Bone Health.
    Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
    World Neurosurg; 2017 Jan; 97():595-602. PubMed ID: 27773859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trabecular bone score as a skeletal fragility index in acromegaly patients.
    Hong AR; Kim JH; Kim SW; Kim SY; Shin CS
    Osteoporos Int; 2016 Mar; 27(3):1123-1129. PubMed ID: 26446771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperprolactinemia: etiology, diagnosis, and management.
    Mah PM; Webster J
    Semin Reprod Med; 2002 Nov; 20(4):365-74. PubMed ID: 12536359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia.
    Schlechte J; Walkner L; Kathol M
    J Clin Endocrinol Metab; 1992 Sep; 75(3):698-703. PubMed ID: 1517357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.